The performance of companies tied to the drug's legacy presents a complex investment scenario . While the initial surge generated substantial profits , generic alternatives have significantly impacted sales . Investing in connected pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving patient trends , and